Based On The Theory Of "blood-water Co-treatment",observe The Clinical Efficacy Of Yi Li Huo Xue Prescription In The Treatment Of Chronic Heart Failure With Yang Deficiency Blood Stasis Syndrome,and Its Effect On NLR,PLR,RDW

Objective:To observe the clinical efficacy and safety in patients with chronic heart failure(CHF)with yang-qi deficiency and blood stasis syndrome of Yi li Huo Xue prescription.The influence of neutrophil-lymphocyte rate(NLR),platelet lymphocyte rate(PLR)and Red cell volume Distribution Width(RDW),To explore the mechanism of Yi li Huo Xue prescription in treating CHF with yang qi deficiency and blood stasis syndrome.Methods:80 patients with Yang Qi deficiency blood stasis syndrome chronic heart failure who met the diagnostic criteria of traditional Chinese and Western medicine and the inclusion criteria from the The People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine were selected.It was randomly divided into the experimental group and the control group,the experimental group was treated with Yi li Huo Xue prescription combined with GDMT for 4 weeks,and the control group was treated with GDMT for 4 weeks,and the changes in clinical symptoms and signs before treatment,after 2 weeks of treatment and after4 weeks of treatment were observed.Using the TCM Syndrome Points,Minnesota quality of life score,Lee’s heart failure score,NYHA cardiac function classification,left ventricular ejection fraction(LVEF),N-terminal pro-B-type natriuretic peptid(NT-pro BNP)for evaluation,and the effect on NLR,PLR,RDW.Result:1.The experimental group and the control group compared the effectiveness of NYHA cardiac function after treatment in CHF patients,89.7% of the experimental group and 71.1%of the control group,the experimental group was better than the control group,and the difference was statistically significant(P<0.05).2 The experimental group and the control group compared the effectiveness of Lee’s score after treatment in CHF patients,89.7% of the experimental group and 76.3% of the control group,the experimental group was better than the control group,and the difference was statistically significant(P<0.05).3.The quality of life score of the CHF patients in the experimental group and the control group after 4 weeks of treatment was significantly lower than that before treatment(P<0.05),comparing the quality of life scores after treatment between the two groups,the experimental group was better than the control group,and the difference was statistically significant(P<0.05).4.The NT-pro BNP of the CHF patients in the experimental group and the control group after 2 weeks and after 4 weeks of treatment was significantly lower than that before treatment(P<0.05),the difference between the two groups after 2 weeks and after 4 weeks of treatment were statistically significant(P<0.05),the 4 weeks after treatment were significantly lower than 2 weeks after treatment(P<0.05),the decline in the experimental group was greater than that of the control group.comparing the two groups,the efficiency was94.9% in the experimental group and 78.9% in the control group,and the difference was statistically significant(P<0.05).5.LVEF of the CHF patients in the experimental group and the control group after 2weeks and after 4 weeks of treatment was significantly higher than that before treatment(P<0.05),and the increase in the experimental group was better than that in the control group,and the difference was statistically significant(P<0.05).6.The TCM Syndrome Points of the CHF patients in the experimental group and the control group after 2 weeks and after 4 weeks of treatment were significantly lower than that before treatment(P<0.05).and 4 weeks after treatment was significantly lower than those after treatment 2 weeks(P<0.05),comparison between the two groups,the experimental group was89.7%,the control group was 71.1%,the difference was statistically significant(P<0.05).Comparing the main symptoms of the two groups after 4 weeks of treatment,the experimental group was better than the control group in the treatment of asthma/wheezing and oedema(P<0.05).7.NLR,PLR and RDW were significantly reduced(P<0.05)after 2 weeks of treatment and after 4 weeks of treatment than before treatment in the experimental group and control group,and the 4 weeks after treatment were significantly lower than 2 weeks after treatment(P<0.05);the difference between the two groups after 2 weeks of treatment and 4 weeks of treatment was statistically significant(P<0.05),and the decline in the experimental group was greater than that of the control group(P<0.05).8.No adverse drug reactions were found in the experimental group and the control group during the observation of efficacy.Conclusion:1.Yi li Huo Xue prescription can effectively reduce the patient’s TCM syndrome score,Lee’s heart failure score,Minnesota quality of life score,NT-pro BNP,NYHA cardiac function grade,and increase LVEF after treatment.2.Yi li Huo Xue prescription can reduce NLR,PLR,RDW in yang deficiency blood stasis CHF patients.3.No adverse reactions were found in the experimental group and the control group.